Instituto Nacional de Enfermedades Respiratorias
Mexico City, 14080, Mexico
NCT Number: NCT03154762
INTRODUCTION: Asthma is a disease characterized by inflammation of the airway and secondary contraction of smooth muscle. Treatment for the crisis consist in the use of local and / or systemic bronchodilators and anti-inflammatories, and it has been shown that mechanical ventilation to the airway through non-invasive positive pressure ventilation (NIPPV) decreases bronchial hyperreactivity and contractility of smooth muscle.
OBJECTIVES: To assess the effect of nocturnal NIPPV on local inflammation, systemic inflammation and the state of hypersensitivity in patients with asthma attack.
MATERIALS AND METHODS: We will include patients with severe asthma attacks requiring hospitalization, without indication for acute NIPPV, and will be randomized to receive NIPPV with an spontaneous (S) bilevel or continuous positive airway pressure (CPAP, control group), all patients will receive standard treatment; gasometric exchange, local inflammation (FEV1 and Exhaled fraction of nitric oxide), systemic inflammation (C reactive protein, IL-4, IL-5, IL-13 and IL-17 in peripheral blood) and the hypersensitivity state (eosinophilia and IgE) between both groups will be compared after 4 days of treatment.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Not applicable
Mexico City, 14080, Mexico
RESEARCH QUESTION What is the effect of non invasive positive pressure ventilation (NIPPV) on systemic inflammation in patients with asthma attacks?
JUSTIFICATION Asthma is a global public health problem and one of the primary causes of care at the National Institute of Respiratory Diseases in Mexico; when presented as a crisis is a serious condition that puts the life of the patient at risk; in vitro and in vivo studies have shown that the application of chronic airway distention using non-invasive mechanical ventilation produces a reduction in bronchial hyperreactivity in patients with asthma and may have a positive effect on the treatment of this condition independent of its effects on ventilation in the presence of acute respiratory failure.
HYPOTHESIS The use of NIPPV will improve systemic inflammation assessed by C reactive protein (CRP) in patients with severe asthmatic crisis.
OBJECTIVES
Main Objective:
To assess the effect of NIPPV on systemic inflammation measure through C reactive protein in acute asthma
Secondary objectives:
MATERIALS AND METHODS
The equipment will be placed at night ad libitum and retired the following day in the morning, in all cases a VPAP ST S8 RESMED will be used. If the patient needs to increase inspired oxygen fraction it will be performed with nasal tips during the day and a distal oxygen connector at night. In all cases a nasal mask will be used.
Blood gasometry, blood cell count, CRP, serum IL-4, IL-5, IL-13, IL-17 and IgE, Spirometry and Exhaled fraction of nitric oxide will be repeated at day 4.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Application of chronic distension of the airway through NIPPV to produce a reduction in bronchial hyperreactivity.
Other names: bilevel
4 cmH2O CPAP as the minimum pressure necessary to mobilize the air flow and avoid the space death with no effect on the ventilation.
Time frame: 4 days
To evaluate the effect of NIPPV on C reactive protein in patients with asthma attacks.
Time frame: 4 days
To evaluate the effect of NIPPV on the days of hospital stay in patients with asthma attacks.
Time frame: 4 days
To evaluate adherence to NIPPV in patients with asthma attacks
Time frame: 4 days
To evaluate the effect of NIPPV on PaCO2, PaO2 and SaO2 in patients with asthma attacks.
Time frame: 4 days
To evaluate the effect of NIPPV on FEV1 and exhaled fraction of nitric oxide in patients with asthma attacks.
Time frame: 4 days.
To evaluate the effect of NIPPV on serum IL-4, IL-5, IL-13 e IL-17 in patients with asthma.attacks.
National Institute of Respiratory Diseases, Mexico
Other Gov
National Institute of Respiratory Diseases Mexico
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07308288
Allergic Rhinitis, Asthma Acute
Naples, Italy
View Trial DetailsNCT03084016
Asthma Acute
Norwich, Norfolk, United Kingdom
View Trial DetailsNCT05318885
Asthma, Asthma Acute
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT03642418
Asthma, Asthma Acute
San Francisco, California, United States
View Trial Details